Artivion
Artivion is a prominent medical device company specializing in the development and manufacturing of innovative solutions for cardiac and vascular surgery. The company focuses on aortic-centric products, offering a comprehensive range that includes aortic and mitral heart valves, aortic allografts, pulmonary human heart valves, pulmonary patches, and various surgical adhesives. Artivion is dedicated to improving patient outcomes through its advanced technologies, which also encompass the preservation and distribution of human tissues for cardiac and vascular reconstruction. By utilizing its proprietary SynerGraft technology, Artivion enhances the performance and safety of its implantable biological devices, surgical adhesives, and biomaterials, serving patients across all age groups. The company's commitment to innovation and quality positions it as a leader in the medical device industry.
EndoSpan
Debt Financing in 2024
EndoSpan Ltd., established in 2008 and headquartered in Herzliya, Israel, specializes in the design and development of innovative stent graft systems under the brand name NEXUS. The company focuses on minimally invasive endovascular repair solutions for aortic arch diseases, including aneurysms and dissections. Its portfolio includes the Endo-Vascular Aortic Aneurysm Repair (EVAR) system, which is tailored for both unilateral and percutaneous approaches. By offering differentiated aortic endografts, EndoSpan aims to address the specific needs of patients with aortic lesions, providing effective treatment options in an underserved clinical area. The company is currently in the pre-clinical stage of development and is backed by venture capital.
Ascyrus Medical
Acquisition in 2020
Ascyrus Medical LLC is a medical device company specializing in the development and manufacture of implantable devices for treating acute Type A aortic dissections. Founded in 2015 by cardiac surgeon Ali Shahriari, the company offers the Ascyrus Medical Dissection Stent (AMDS), which aims to reduce complications and the need for reoperations by sealing the distal anastomotic new entry and restoring blood flow to the true lumen. The device also facilitates rapid deployment in the aortic arch during conventional ascending aorta replacement procedures, thereby buttressing and strengthening the aortic tissue. With a focus on minimizing the complexities and risks associated with aortic dissections, Ascyrus Medical is headquartered in Boca Raton, Florida, with an additional office in Frankfurt, Germany. As of September 2020, the company operates as a subsidiary of CryoLife, Inc.
EndoSpan
Venture Round in 2019
EndoSpan Ltd., established in 2008 and headquartered in Herzliya, Israel, specializes in the design and development of innovative stent graft systems under the brand name NEXUS. The company focuses on minimally invasive endovascular repair solutions for aortic arch diseases, including aneurysms and dissections. Its portfolio includes the Endo-Vascular Aortic Aneurysm Repair (EVAR) system, which is tailored for both unilateral and percutaneous approaches. By offering differentiated aortic endografts, EndoSpan aims to address the specific needs of patients with aortic lesions, providing effective treatment options in an underserved clinical area. The company is currently in the pre-clinical stage of development and is backed by venture capital.
EndoSpan
Debt Financing in 2019
EndoSpan Ltd., established in 2008 and headquartered in Herzliya, Israel, specializes in the design and development of innovative stent graft systems under the brand name NEXUS. The company focuses on minimally invasive endovascular repair solutions for aortic arch diseases, including aneurysms and dissections. Its portfolio includes the Endo-Vascular Aortic Aneurysm Repair (EVAR) system, which is tailored for both unilateral and percutaneous approaches. By offering differentiated aortic endografts, EndoSpan aims to address the specific needs of patients with aortic lesions, providing effective treatment options in an underserved clinical area. The company is currently in the pre-clinical stage of development and is backed by venture capital.
JOTEC GmbH, founded in 2000 and headquartered in Hechingen, Germany, specializes in the development, manufacturing, and marketing of medical devices for aortic and peripheral vascular diseases. The company's product portfolio includes surgical vascular prostheses, endovascular stent grafts, and interventional implants designed for vascular and cardiac surgery, as well as interventional radiology and cardiology. JOTEC offers a variety of grafts, including ePTFE and polyester options, along with stents and stent graft systems for treating aortic diseases. Its offerings also include specialized products such as supported elephant trunk grafts and various accessories like sheaths and guide wires. As of December 2017, JOTEC operates as a subsidiary of CryoLife, Inc.
On-X Life Technologies
Acquisition in 2015
On-X Life Technologies Inc. specializes in the development, manufacturing, and marketing of artificial heart valve replacement and repair products. The company's diverse product portfolio includes aortic and mitral heart valves equipped with standard, anatomic, and Conform-X sewing rings, as well as ascending aortic prostheses and chordal repair products. Additionally, On-X offers cardiovascular specialty products and provides technical services related to carbon-based technology, encompassing medical design, product development, and manufacturing. Founded in 1994 and based in Austin, Texas, the company was previously known as Medical Carbon Research Institute and rebranded in 2007. As of January 2016, On-X operates as a subsidiary of CryoLife Inc.
Hemosphere
Acquisition in 2012
Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.
ValveXchange
Venture Round in 2011
ValveXchange, Inc. develops two-part bioprosthetic tissue valves that resolve the compromises between conventional mechanical and tissue heart valves. It offers Vitality exchangeable heart valve systems; Vitality exchangeable tissue valves; valve delivery and exchange systems; transapical implants and exchanges; and apical introducers. ValveXchange is based in Aurora, Colorado.
Cardiogenesis Corporation
Acquisition in 2011
Cardiogenesis Corporation designs, develops, and distributes laser-based surgical products and disposable fiber-optic accessories for the treatment of cardiac ischemia associated with advanced cardiovascular disease. The company offers minimally-invasive transmyocardial revascularization fiberoptic delivery, robotic hand piece delivery, and complete console and cardiovascular delivery systems. Additionally, Cardiogenesis provides reimbursement services. Cardiogenesis pioneered the development of Transmyocardial revascularization (TMR) procedures, a method of therapy and treatment for refractive angina that is approved by the American College of Cardiology, American Heart Association, and the Society of Thoracic Surgery. Cardiogenesis was founded in 1989 and is headquartered in Kennesaw, Georgia. As of May 17, 2011, Cardiogenesis Corporation operates as a subsidiary of CryoLife Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.